Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II

This publication has 18 references indexed in Scilit:

• Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), a novel topoisomerase I and II inhibitor, in cancer patients
  Anti-Cancer Drugs, 1996
• Experimental solid tumour activity ofN-[2-(dimethylamino)ethyl]-acridine-4-carboxamide
  Cancer Chemotherapy and Pharmacology, 1995
• Microculture-Based Chemosensitivity Testing: A Feasibility Study Comparing Freshly Explanted Human Melanoma Cells With Human Melanoma Cell Lines
  JNCI Journal of the National Cancer Institute, 1992
• Effects of CPT‐11 in combination with other anti‐cancer agents in culture
  International Journal of Cancer, 1992
• Design of NDA Intercalators To Overcome Topoisomerase II-Mediated Multidurg Resistance
  JNCI Journal of the National Cancer Institute, 1990
• Selectivity of N-[2-(Dimethylamino)ethyl]acridine-4-car☐amide towards Lewis lung carcinoma and human tumour cell lines in vitro
  European Journal of Cancer and Clinical Oncology, 1989
• Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II
  European Journal of Cancer and Clinical Oncology, 1988
• Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D.
  Proceedings of the National Academy of Sciences, 1988
• Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide
  Journal of Medicinal Chemistry, 1987
• Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II.
  Journal of Biological Chemistry, 1984